Frontiers | Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk | Pharmacology
![canagliflozin [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/sglt2.png "canagliflozin [TUSOM | Pharmwiki]")
canagliflozin [TUSOM | Pharmwiki]
SGLT-2 inhibitors in diabetes: a focus on renoprotection
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus | Cardiovascular Diabetology | Full Text
Canagliflozin (Mechanism of action) | Download Scientific Diagram
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ...
Mechanism of action of canagliflozin on SGLT-2 in the renal proximal... | Download Scientific Diagram
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors - Kidney International
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease | SpringerLink
Introduction to SGLT2 Inhibition - YouTube
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research | Diabetes
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome | American Society of Nephrology
Mechanism of action of canagliflozin on SGLT-2 in the renal proximal... | Download Scientific Diagram
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors - Yakovleva -
SGLT2 inhibitors
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure | Heart
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus - ScienceDirect
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation - American Journal of Kidney Diseases
SGLT2 Inhibitors: A Review of Canagliflozin
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors - Brown - 2019 - Diabetes, Obesity and Metabolism - Wiley Online Library
Top 10 Things Invokana Patients Need To Know... - Childers, Schlueter & Smith, LLC
Swiss Medical Weekly - Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
Update on Mx of T 2 DM Emerging
Canagliflozin - an overview | ScienceDirect Topics
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure | SpringerLink
